On May 15, 2018 Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, reported that it will present results from eight studies at the 2018 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting to be held June 1 to 5, 2018 in Chicago, Ill (Press release, Myriad Genetics, MAY 15, 2018, View Source [SID1234526646]). Abstracts of the Company’s presentations will be available at: abstracts.asco.org on May 16 at 5:00 p.m. EDT.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We look forward to presenting exciting new discoveries at ASCO (Free ASCO Whitepaper) that we believe will expand the reach of personalized medicine for patients with cancer," said Johnathan Lancaster, M.D., Ph.D., chief medical officer, Myriad Genetics. "Importantly, our presentations will focus on new advances in predicting breast cancer recurrence and the need for chemotherapy, the role of hereditary cancer testing in preventing cancer or optimizing treatment plans, and novel companion diagnostics for helping guide medication selection for patients with breast or ovarian cancers."
A list of Myriad presentations at ASCO (Free ASCO Whitepaper) 2018 are below. Follow Myriad on Twitter via @MyriadGenetics and stay informed about symposium news and updates by using the hashtag #ASCO18.
Title Presenter Abstract Number Day/Time Myriad Product
Oral Presentation
Validation of a Combined Residual Risk Score
for Healthy Unaffected Women Presenting to Breast
Cancer (BC) Screening Centers Kathryn Dalton Presentation 1507 Sunday, June 3, 2018: 8:00-11:30 a.m. CDT. riskScore
Poster Presentations
Predicting Expected Absolute Chemotherapy
Treatment Benefit in Women with Early-Stage
Breast Cancer using a 12-Gene Expression
Assay William Gradishar Abstract 525 Saturday, June 2, 2018: 8:00-11:30 a.m. EndoPredict
In Silico Evaluation of the 12-gene molecular
score (EndoPredict) and the Recurrence Score
(Oncotype DX) as Predictors of Response to
Neo-adjuvant Chemotherapy in Estrogen
Receptor Positive (ER+), HER2 Negative
(HER2-) Breast Cancer Hatem Soliman Abstract 539
Saturday, June 2, 2018: 8:00-11:30 a.m. CDT. EndoPredict
Promoting Colorectal Cancer (CRC) Screening
after Multiplex Genetic Testing and Genetic
Counselling Gregory Idos Abstract 1582 Saturday, June 2, 2018: 1:15-4:45 p.m. CDT.
Myriad myRisk
Promoting Breast Cancer Screening after
Multiplex Genetic Panel Testing (MGPT) and
Genetic Counselling Gregory Idos Abstract 1581 Saturday, June 2, 2018: 1:15-4:45 p.m. CDT.
Myriad myRisk
Evaluation of Homologous Recombination
Deficiency (HRD) status with pathological
response to carboplatin +/- veliparib
in BrighTNess, a randomized phase 3 study in
early stage TNBC Melinda Telli Abstract 519 Saturday, June 2, 2018: 3:00-4:15 p.m. CDT. myChoice HRD
Locus-specific loss of heterozygosity (LOH) in
BRCA1/2 mutated (mBRCA) ovarian tumors
from the SOLO2 (NCT01874353) and Study 19
(NCT00753545) clinical trials Kirsten Timms Abstract 5563 Monday, June 4, 2018: 1:15-4:45 p.m. CDT.
myChoice HRD
About EndoPredict
EndoPredict is a second-generation, multigene prognostic test for patients diagnosed with ER+, HER2- early-stage breast cancer. The test provides physicians with information to devise personalized treatment plans for their patients. EndoPredict has been validated in approximately 4,000 patients with node-negative and node-positive cancer and has been used clinically in more than 20,000 patients. In contrast to first-generation multigene prognostic tests, EndoPredict detects the likelihood of late metastases (i.e., metastasis formation after more than five years) and, therefore, can guide treatment decisions regarding the need for chemotherapy, as well as extended anti-hormonal therapy. Accordingly, therapy decisions backed by EndoPredict confer a high level of diagnostic safety. For more information, please visit: www.endopredict.com.
About Myriad myRisk Hereditary Cancer
The Myriad myRisk Hereditary Cancer panel uses validated technologies and algorithms in an 850 step laboratory process to evaluate 28 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma. For more information, please visit: View Source
About riskScoreTM
riskScore is a clinically validated algorithm that predicts a women’s remaining 5-year and lifetime risk of developing breast cancer. The algorithm combines the analysis of over 80 well-studied genetic markers and the Tyrer-Cuzick model to accurately estimate breast cancer risk for woman of European descent. For more information, please visit: View Source
About myChoice HRD
Myriad’s myChoice HRD is the first homologous recombination deficiency test that can detect when a tumor has lost the ability to repair double-stranded DNA breaks, resulting in increased susceptibility to DNA-damaging drugs such as platinum drugs or PARP inhibitors. High myChoice HRD scores reflective of DNA repair deficiencies are prevalent in all breast cancer subtypes, ovarian and most other major cancers. In previously published data, Myriad showed that the myChoice HRD test predicted drug response to platinum therapy in certain patients with triple-negative breast and ovarian cancers. It is estimated that 1.8 million people in the United States and Europe who are diagnosed with cancers annually may be candidates for treatment with DNA-damaging agents. For more information, please visit: View Source